In case you missed it...

...make sure you get your free "Simple Options Trading For Beginners" book before your link expires.

I eventually plan to charge money for this training, so do yourself a favor and download it now...

That way, no matter what it costs in the future, you'll have a free copy.

Sound good?

FREE: Simple Options Trading For Beginners << Get It Now

Good Trading,
Bill Poulos

p.s. Go here to save a copy of your "Simple Options Trading For Beginners" book while it's still free.

5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama

Submitted by Ryan Hasson. Date Posted: 7/20/2026.

Apple (NASDAQ: AAPL) closed Friday within half a percent of its all-time high. Altria (NYSE: MO) finished a stone's throw from its 52-week high, about 1.6% below that key level. JPMorgan (NYSE: JPM) is also pressing near record levels and quickly closing in on a $1 trillion valuation. If none of that sounds familiar, it is because almost nobody is talking about it.

The market's attention has been locked on the correction ripping through the AI trade, and understandably so, given how far and fast the sector's leaders have fallen from their peaks. But markets rarely reward the crowd for staring at the same story. While the drama unfolds, a group of blue-chip stocks spanning healthcare, tobacco, beverages, banking, and consumer technology has been quietly grinding to new highs, with several set to report earnings in the next two weeks.

Last week alone, while a tech sell-off hit the S&P 500 and Nasdaq, financials and other defensive groups gained ground. Here are five stocks making highs in the shadows, and why each deserves attention now.

Johnson & Johnson: A Blowout Quarter Nobody Noticed

Johnson & Johnson (NYSE: JNJ) just delivered one of the strongest reports of the season so far, and it barely made a ripple outside healthcare circles. The company beat on both revenue and earnings on July 15, raised full-year guidance, and attracted a round of analyst price-target increases.

That was followed days later by a spine technology acquisition and FDA clearance for a new heart device. The stock is up close to 22% year-to-date and sits roughly 6% below its 52-week high of $269.43. The recent pullback from that peak is beginning to look like a potential buying opportunity. Following its results, the stock is holding above prior resistance near $250. If it confirms that level as new support, a fresh leg higher could follow.

The fundamentals are exactly what defensive capital looks for: a stellar Q2 report and forward guidance, a forward price-to-earnings (P/E) ratio under 22, a 2.2% yield backed by more than six decades of consecutive dividend increases, and a beta of just 0.24, the lowest of any name on this list. J&J scores in the 90th percentile of MarketBeat's MarketRank. The talc litigation remains the known overhang to watch, but with a consensus Moderate Buy rating from 26 analysts, the market's quiet accumulation of this name tells its own story.

Altria: The Best-Performing Boring Stock

Altria might be the least glamorous stock on this list, yet it has quietly outperformed almost everything outside the AI complex this year. Shares are up close to 28% year-to-date, closing Friday within roughly 2% of a fresh 52-week high set earlier last week. Notably, the stock rose more than 2% last week while the broader market fell, the textbook definition of relative strength.

From a technical perspective, the stock's setup is classically bullish after a multi-month sideways consolidation near its 52-week high. For the higher-timeframe breakout to be more fully confirmed, the stock will need to convincingly clear that high near $75.

The fundamental case has improved, too. New FDA rule proposals targeting foreign tobacco manufacturers were flagged this week as a direct tailwind for Altria's domestic franchise. Several analysts have taken bullish action this month, with analysts from Weiss Ratings and UBS Group rating the stock a Buy and UBS boosting its target from $76 to $79.

The stock still trades at just 13 times forward earnings while paying a 5.7% yield backed by more than 55 consecutive years of dividend increases. One important factor for potential investors to note, however, is that the consensus rating remains Hold, with a price target below the current price. Earnings arrive on July 30 for the defensive giant, a potential catalyst that could lead to a re-rating of targets.

Coca-Cola: A Dividend King Marching Higher

Coca-Cola (NYSE: KO) has spent 2026 doing what it does best: quietly compounding. The stock is up almost 17% year-to-date, trading near $81.50, and has recently reached a new 52-week high of $85.68.

Last Thursday brought a rare stumble, with shares dipping almost 5% after a ransomware attack forced a temporary halt to production at its Fairlife dairy operation. That headline is worth watching, but for investors, it is an operational disruption, not a demand story.

The underlying quality here remains elite for the global beverage giant. Coca-Cola scores in the 93rd percentile of MarketBeat's MarketRank, ranking 14th out of 148 consumer staples stocks, with trailing 12-month net margins near 28% and a return on equity above 40%. The 2.6% yield is backed by 64 consecutive years of dividend increases, and the beta of 0.34 makes it one of the steadiest large caps in the market. The consensus price target of $88.81 across 16 analysts implies almost 9% upside, and earnings arrive on July 28, a significant near-term catalyst to watch.

JPMorgan Chase: Record Highs and a $1 Trillion Milestone in Sight

JPMorgan Chase is the clearest example of where rotating capital has been flowing. Financials were among the strongest groups during last week's tech sell-off, and JPMorgan enters the new week near $342, about 3% below its 52-week high of $351.24. With a market cap of almost $915 billion, that puts a $1 trillion valuation, unprecedented for a U.S. bank, within reach.

The Q2 report on July 14 provided fresh support for JPM's bullish price action.

Revenue of $58 billion and earnings per share (EPS) of $6.14 both topped expectations, driven by strong loan growth. That prompted a round of upward analyst price targets and a likelihood of a double-digit dividend increase in September.

At about 15 times earnings, JPMorgan remains one of the cheapest names on this list despite being arguably the best-run bank in the world. It scores in the 91st percentile of MarketBeat's MarketRank, with a healthy short interest score and strong dividend strength score.

When the highest-quality financial in America is pressing all-time highs while growth stocks correct, it says something about where institutional money is moving.

Apple: The Mega-Cap Tech Exception at All-Time Highs

Apple is the fascinating outlier on this list, an almost $4.9 trillion technology company trading at all-time highs while the rest of big tech corrects. The stock closed Friday at $333.35, within half a percent of its record high, and is up about 23% year-to-date.

While the market debates AI CapEx and chip valuations, Apple has quietly become a perceived safe haven within technology, helped by reports of massive capital flows shifting toward it and by its steadier, services-driven earnings profile.

The setup heading into its July 30 Q3 earnings report carries real tension. Apple's AI monetization thesis faces its biggest test yet, with rising component costs and a forward multiple near 38 giving skeptics ammunition. The consensus price target of $322.43 now sits below the share price, while several insiders have been selling over the past 12 months. But with close to $112 billion in trailing 12-month net income and a strong dividend rating, Apple has earned its premium the old-fashioned way. Whether it can defend record highs through earnings is one of the more important questions of the next two weeks.

The Quiet Trade Is Working

One important takeaway stands out from all of the above. While the market's attention is fixated on the AI drama, capital has been rotating steadily into quality, income, and durability, and for many names it has been paying off. Two Dividend Kings, the nation's premier bank, healthcare's most reliable blue chip, and one of the world's largest companies are all at or near their highs, most with earnings arriving within the next two weeks. In that regard, momentum and safety are not always opposites. Right now, some of the market's best momentum is hiding in its safest names.

Editor's Note: Robert Kiyosaki, author of Rich Dad Poor Dad, the #1 personal finance book of all time with over 40 million copies sold, has spent decades teaching everyday Americans how the wealthy actually build income. He called the 2008 housing crash before it happened, warned investors to buy gold and silver well before their historic runs, and has been pounding the table on cash-flowing assets for over 30 years. Today, he'll show you an income play funded entirely by America's oil and gas infrastructure. One that's already paying some investors $25,000 a month and is the closest thing to universal basic income that may ever exist. Click here to see the details or read more below.

Saudi Arabia figured it out.

They pay their citizens $3,600 a month per family. Just for existing. Funded entirely by oil.

Meanwhile, politicians in America are arguing about Twitter, while you get nothing from the $300 billion we generate from oil and gas every year.

But there is a way to collect.

It's called the Patriot Income Plan, or P.I.P. for short.

It's not a government program. It's not a stimulus check. It's not tied to an election or a budget vote.

It's direct ownership in 14 entities that control America's energy infrastructure — pipelines, terminals, processing plants — and pay 10% a year to everyone who holds units.

Put in $10,000 = get $1,000 back.
Put in $50,000 = get $5,000 back.
Put in $100,000 = get $10,000 back.

42 payouts a year. Deposited automatically.

This is universal basic income for people who don't want to wait around for the government to figure it out.

P.I.P. is on pace to pay out $53 billion this year — a record. The next distribution drops in days.

Here's how to enroll

Sincerely,
Robert Kiyosaki
Editor, The Kiyosaki Letter

Achieve Robust Diversification With These 3 Equal-Weight ETFs

Author: Nathan Reiff. Date Posted: 7/13/2026.

Exchange-traded funds (ETFs) remain among the most popular investment vehicles, with inflows in the first half of 2026 reaching a record $1 trillion across the ETF universe. Investors continue to flock to these funds for their ready-made diversification, since a single trade can provide access to dozens, hundreds or even more stocks and securities. However, investors who do not pay close attention to an ETF's methodology and weighting structure may end up with a less diversified portfolio than they expected.

Many ETFs track indexes that weight assets by market capitalization or other factors, which can create significant imbalances within a basket. For example, an investor expecting broad exposure to a sector or industry may instead end up with heavy exposure to a handful of names and much less exposure to the rest of the group. This is not necessarily a problem, but it is something many investors overlook. One solution for investors seeking greater balance across an ETF's entire basket is to focus on equal-weight funds like those listed below.

An Alternative to Traditional S&P 500 Funds

When most investors think of the S&P 500, they think of the free-float market-cap-weighted index in which the largest companies hold the most sway. However, the Invesco S&P 500 Equal Weight ETF (NYSEARCA: RSP) tracks an equal-weight version of the index made up of the same stocks. This creates exposure that is far more balanced across the index, although it can come at the expense of outperformance when the largest companies in the S&P 500 are thriving.

As investors might expect, RSP holds just over 500 positions, none of which represents more than about a third of a percent of the overall portfolio. By comparison, a fund like the SPDR S&P 500 ETF Trust (NYSEARCA: SPY)—a go-to fund that tracks the S&P 500 index—has largest holdings that represent 7% or more.

In the case of RSP, the equal-weighting approach offers not only greater risk mitigation but also improved performance so far in 2026. The fund has returned close to 12% year to date (YTD), beating the broader S&P 500 in the process. In exchange, investors must be prepared to pay a bit more, as RSP has an annual fee of 0.20%, substantially higher than the cheapest broad S&P funds.

Equal Weighting for the Nasdaq-100

The First Trust NASDAQ-100 Equal Weighted Index Fund (NASDAQ: QQEW) takes a similar approach to RSP, but with a focus on the Nasdaq-100 Index instead of the S&P 500. The Nasdaq-100 weights its collection of major non-financial companies using a modified market-cap approach, leading to some positions in Nasdaq-100 ETFs being significantly larger than others.

QQEW equalizes its roughly 52 holdings so that each represents no more than about 2.8% of the basket. This can help reduce some of the tech-sector overweighting that occurs in traditional Nasdaq-100 funds. However, because of the smaller number of positions overall and the importance of tech stocks to the broader Nasdaq-100 index, equal weighting does not completely eliminate the bias toward tech.

This fund has returned nearly 12% YTD and carries a higher expense ratio of 0.55%. It also has fairly modest assets under management (AUM) and trading volume, making it perhaps more appropriate for less active, buy-and-hold investors than for those seeking regular liquidity.

A Take on the Fortune 500 List With Equal Weighting

Yet another equal-weighting approach can be found with the DoubleLine Fortune 500 Equal Weight ETF (NYSEARCA: DFVE), an ETF dedicated to an equal-weight version of the Fortune 500 list. The Fortune 500 tracks the largest companies in the United States by revenue, rather than market cap, so it can diverge significantly from the S&P 500.

DFVE holds around 467 positions, mostly large- and mid-cap stocks, with the largest position accounting for only about 0.39% of the total portfolio. So far this year, it has returned just under 13% YTD, and the expense ratio of this fund is on par with RSP at 0.20%. One caveat for potential investors is that DFVE has substantially lower AUM and average trading volume than the other funds on this list, suggesting liquidity may be more of an issue. Still, for long-term investors seeking an alternative to the S&P 500 and equal weighting, DFVE may be worth considering.